Ceapro Inc., a biotechnology company, engages in developing and commercializing active ingredients in the United States, Germany, China, Canada, and internationally. More Details
Flawless balance sheet with questionable track record.
Share Price & News
How has Ceapro's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CZO's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CZO exceeded the Canadian Chemicals industry which returned -14.6% over the past year.
Return vs Market: CZO exceeded the Canadian Market which returned -3.9% over the past year.
Price Volatility Vs. Market
How volatile is Ceapro's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs Ceapro (CVE:CZO) Likely To Turn Things Around?
2 months ago | Simply Wall StDid Business Growth Power Ceapro's (CVE:CZO) Share Price Gain of 256%?
3 months ago | Simply Wall StCan Mixed Fundamentals Have A Negative Impact on Ceapro Inc. (CVE:CZO) Current Share Price Momentum?
Is Ceapro undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CZO (CA$0.75) is trading above our estimate of fair value (CA$0.42)
Significantly Below Fair Value: CZO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CZO is good value based on its PE Ratio (25.6x) compared to the CA Chemicals industry average (28.8x).
PE vs Market: CZO is poor value based on its PE Ratio (25.6x) compared to the Canadian market (16.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CZO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CZO is overvalued based on its PB Ratio (2.4x) compared to the CA Chemicals industry average (2.2x).
How is Ceapro forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CZO's forecast earnings growth is above the savings rate (1.7%).
Earnings vs Market: Insufficient data to determine if CZO's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CZO's revenue (9.2% per year) is forecast to grow faster than the Canadian market (5.8% per year).
High Growth Revenue: CZO's revenue (9.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CZO's Return on Equity is forecast to be high in 3 years time
How has Ceapro performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CZO has high quality earnings.
Growing Profit Margin: CZO became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CZO's earnings have declined by 49% per year over the past 5 years.
Accelerating Growth: CZO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CZO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (-17.5%).
Return on Equity
High ROE: CZO's Return on Equity (9.2%) is considered low.
How is Ceapro's financial position?
Financial Position Analysis
Short Term Liabilities: CZO's short term assets (CA$8.9M) exceed its short term liabilities (CA$1.2M).
Long Term Liabilities: CZO's short term assets (CA$8.9M) exceed its long term liabilities (CA$3.1M).
Debt to Equity History and Analysis
Debt Level: CZO's debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: CZO's debt to equity ratio has reduced from 149.4% to 0.7% over the past 5 years.
Debt Coverage: CZO's debt is well covered by operating cash flow (1718.4%).
Interest Coverage: CZO's interest payments on its debt are well covered by EBIT (13.4x coverage).
What is Ceapro current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CZO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CZO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CZO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CZO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CZO's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Gilles Gagnon (66 yo)
Mr. Gilles R. Gagnon, M.Sc., MBA, ICD.D, serves as Director at Aeterna Zentaris Inc. since January 1, 2020. He serves as the President of Spectrum Pharma Canada Inc. (Spectrum Canada). Mr. Gagnon has been ...
CEO Compensation Analysis
Compensation vs Market: Gilles's total compensation ($USD394.05K) is above average for companies of similar size in the Canadian market ($USD171.35K).
Compensation vs Earnings: Gilles's compensation has been consistent with company performance over the past year.
|CEO, President & Director||8.25yrs||CA$518.00k||1.73% |
|Independent Director||5.92yrs||CA$45.84k||0.13% |
|Independent Director||22.75yrs||CA$42.67k||2.32% |
|Independent Director||21.75yrs||CA$37.67k||1.34% |
|Independent Chairman of the Board||6yrs||CA$47.67k||1.48% |
|Independent Director||5.5yrs||CA$49.81k||0.10% |
Experienced Board: CZO's board of directors are considered experienced (9.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ceapro Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Ceapro Inc.
- Ticker: CZO
- Exchange: TSXV
- Founded: 1997
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: CA$58.209m
- Shares outstanding: 77.61m
- Website: https://www.ceapro.com
- Ceapro Inc.
- 7824 – 51 Avenue NW
- T6E 6W2
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CZO||TSXV (TSX Venture Exchange)||Yes||Class A Voting Common Shares||CA||CAD||Sep 1988|
|CRPO.F||OTCPK (Pink Sheets LLC)||Yes||Class A Voting Common Shares||US||USD||Sep 1988|
|385||DB (Deutsche Boerse AG)||Yes||Class A Voting Common Shares||DE||EUR||Sep 1988|
Ceapro Inc., a biotechnology company, engages in developing and commercializing active ingredients in the United States, Germany, China, Canada, and internationally. It operates through two segments, The A ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/25 00:52|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.